- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
- Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
- Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
- Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
- Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
- Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
More ▼
Key statistics
On Wednesday, Vir Biotechnology Inc (VIR*:MEX) closed at 172.00, 0.00% below its 52-week high of 172.00, set on Sep 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 172.00 |
Average volume | -- |
---|---|
Shares outstanding | 136.06m |
Free float | 120.14m |
P/E (TTM) | -- |
Market cap | 1.32bn USD |
EPS (TTM) | -4.01 USD |
Data delayed at least 20 minutes, as of Sep 13 2023 12:30 BST.
More ▼